State Street SPDR S&P Biotech ETF
713 hedge funds and large institutions have $7.23B invested in State Street SPDR S&P Biotech ETF in 2023 Q1 according to their latest regulatory filings, with 76 funds opening new positions, 229 increasing their positions, 237 reducing their positions, and 95 closing their positions.
15.89% more ownership
Funds ownership: 94.86% → 110.75% (+16%)
3% less repeat investments, than reductions
Existing positions increased: 229 | Existing positions reduced: 237
4% less funds holding
Funds holding: 746 → 713 (-33)
12% less capital invested
Capital invested by funds: $8.21B → $7.23B (-$977M)
20% less first-time investments, than exits
New positions opened: 76 | Existing positions closed: 95
26% less funds holding in top 10
Funds holding in top 10: 31 → 23 (-8)
32% less call options, than puts
Call options by funds: $1.15B | Put options by funds: $1.7B
Top Buyers
| 1 |
JP Morgan Chase
New York
|
+$401M |
| 2 |
Barclays
London,
United Kingdom
|
+$284M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$115M |
| 4 |
Jane Street
New York
|
+$96.4M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$85.4M |
Top Sellers
XBI Hedge Fund Activity: Q1 2023 in Review
713 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q1 2023, worth a combined $7.23B — down 12% from $8.21B a quarter earlier.
Sellers outnumbered buyers: 95 funds closed out of XBI and 76 opened new positions — a net loss of 19 holders — while 237 trimmed existing stakes and 229 added.
The largest buyer was JP Morgan Chase, adding an estimated $401M. The largest seller was Moore Capital Management, cutting an estimated $241M.
- 713 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q1 2023, down from 746 in Q4 2022.
- Funds reported $7.23B of State Street SPDR S&P Biotech ETF stock for Q1 2023, down 12% quarter-over-quarter.
- 76 funds opened new State Street SPDR S&P Biotech ETF positions in Q1 2023 and 95 closed out, a net change of -19 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q1 2023 was JP Morgan Chase, an estimated $401M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q1 2023 was Moore Capital Management, an estimated $241M sold.
Based on aggregated 13F filings for Q1 2023.